Focusight (hereinafter referred to as“Focusight”) CompletedPre-ARound of financing,Fong Capital Partners Exclusive Investment。This round of funding will be used to promote the company.Digital Therapy for Amblyopia Across All Age Groups, and accelerate the landing of digital therapeutics products for strabismus, glaucoma, presbyopia, etc.
Focusight was founded in2020Year, is aAn Innovative Ophthalmology Diagnosis and Treatment Platform Driven by Brain Science Mechanism Research. The company is committed to“Basic Neuroscience+Research on the Mechanism of Eye Diseases+Wearable Intelligent Products”Build CoverageA Comprehensive Diagnostic and Treatment Platform for Eye Diseases Such as Amblyopia, Strabismus, Myopia, Glaucoma, and Presbyopia. The core team of the company consists of serial entrepreneurs, brain science experts, clinical ophthalmologists, andAIComposed of engineers, withThe Full Chain Closed Loop from Scientific Research to IndustrializationAbility.
Focusight's amblyopia treatment product breaks“Amblyopia in Older Age is Incurable”This traditional clinical understanding. Relying on the world's leading ophthalmology diagnosis and treatment solutions driven by brain cognition, the company has deepened its innovative product portfolio, developing more products that align with clinical pathways and personalized needs.of highly compliant diagnostic and therapeutic products, providing patients withComprehensive, Full-Life-Cycle Ophthalmic Health Management Solutions。
A project leader of Fong Capital Partners stated: "We highly recognize Focusight in...The Intersection of Neuroscience and OphthalmologyThe original exploration. They not only solved a clear clinical pain point but also built a highly scalable platform-based technical foundation. We are optimistic about its 'The Disruptive Potential of the 'Soft-Hard Integration' Model in the Future Ophthalmic Diagnosis and Treatment Market。”
Fong Capital Partners is a dual-currency equity investment firm focused on the medical and technology sectors, with offices in Beijing, Shanghai, and Hong Kong. Fong Capital PartnersThe core team has been cooperating for over 10 years, possessing extensive management experience in both RMB funds and US dollar funds, with a past management scale exceeding 8 billion yuan. They have abundant industrial resources in the medical and technology fields. Adhering to the investment philosophy of continuous focus, precise layout, and in-depth industry cultivation, the Fong Capital Partners team has delivered stable and sustained excellent returns to investors over the past decade, earning continuous recognition from multiple institutional investors both domestically and internationally.Fong Capital Partners insists on empowering invested companies from all aspects, including industry-university-research cooperation, clinical resources, sales resources, and regulatory resources, acting as a partner to the invested companies and using the most professional capabilities to help businesses grow. Past star cases include Sonoscape Technology (Stock Code:300633, Leader in medical ultrasound equipment and endoscopic devices),DJI (The world's leading drone brand), Transsion Holdings (Stock Code: 688036，The largest mobile phone brand in Africa)、Ronbay Lithium (Stock Code: 688005, China's R&D and manufacturing company for cathode materials of power lithium batteries), ResMed (Stock Code: 301367, the No.1 brand of Chinese home respiratory equipment), Insilico Medicine(Stock Code: 3696.HK, Global AI Pharmaceutical Leader)etc.
